Humacyte CSO Jeffrey Lawson to depart effective Dec 31, 2022; no disagreement cited

Humacyte, Inc.

Dr. Jeffrey H. Lawson, Chief Surgical Officer, leaves Humacyte effective Dec 31, 2022, and resigns from board.
Departure is mutual, not due to any disagreement with company operations, policies, or practices.
Severance benefits per existing employment agreement; vested stock option exercise period extended to Nov 26, 2022.
Separation agreement includes customary release of claims and supersedes other severance arrangements.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jeffrey H. Lawson

Director

HUMA · Humacyte, Inc.

Effective: 2022-12-31
Filed: December 27, 2021, 6:59 PM ET

Dr. Lawson also resigned from the Company’s board of directors, effective as of the Separation Date.

Departed

Jeffrey H. Lawson

Chief Surgical Officer

HUMA · Humacyte, Inc.

Effective: 2022-12-31
Filed: December 27, 2021, 6:59 PM ET

On December 23, 2021, Humacyte, Inc. (the “Company”) and Jeffrey H. Lawson, M.D., Ph.D., the Company’s Chief Surgical Officer, mutually agreed to end Dr. Lawson’s employment with the Company, effective December 31, 2022 (the “Separation Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeffrey H. Lawson resigned as Director at Humacyte, Inc..

Action: resigned
Role: Director

Exact text from the filing

Dr. Lawson also resigned from the Company’s board of directors, effective as of the Separation Date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeffrey H. Lawson resigned as Chief Surgical Officer at Humacyte, Inc..

Action: resigned
Role: Chief Surgical Officer

Exact text from the filing

On December 23, 2021, Humacyte, Inc. (the “Company”) and Jeffrey H. Lawson, M.D., Ph.D., the Company’s Chief Surgical Officer, mutually agreed to end Dr. Lawson’s employment with the Company, effective December 31, 2022 (the “Separation Date”).

View on SEC.gov

Humacyte, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-21-153559

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.